Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics, Hitachi Partner on Data-Driven Precision Medicine

NEW YORK – Sophia Genetics and Hitachi said on Thursday that they have signed a long-term collaboration deal to extend data-driven precision medicine to healthcare providers and pharmaceutical companies worldwide.

The companies said that they would initially cooperate to expand the reach of Sophia's core DDM analytics platform and various Hitachi digital healthcare offerings, including its molecular tumor board support service, in "key geographies." They also hope to collaborate on secure personal genomics data management, data-driven clinical decision support, and the acceleration of drug development in oncology and other areas, as well as to codevelop new products in the longer term.

"This partnership will enable us to broaden our commercial reach and support improved health outcomes for more patients," Jurgi Camblong, CEO of Lausanne, Switzerland-based Sophia, said in a statement.

"Hitachi is excited to start [a] long-term partnership with Sophia Genetics to co-create innovative solutions for improving quality of life of patients by leveraging both companies' data analytics and AI technologies," added Keiji Kojima, executive VP and executive officer of Hitachi and general manager of its Smart Life Business Management Division.

Hitachi's investment arm, Hitachi Ventures, already has an equity stake in Sophia. The Japanese firm co-led a $110 million investment round in Sophia last year.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.